Format

Send to

Choose Destination
Clin Infect Dis. 2016 Jan 15;62(2):258-261. doi: 10.1093/cid/civ841. Epub 2015 Sep 22.

A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Author information

1
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland.
2
Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston.
3
Leidos Biomedical Research, Inc, Frederick, Maryland.

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

KEYWORDS:

immune reconstitution inflammatory syndrome; infliximab; mycobacterial infection

PMID:
26394669
PMCID:
PMC4690485
DOI:
10.1093/cid/civ841
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center